



A global leader in providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions



Xellia Pharmaceuticals is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as finished dosage forms, where the majority are injectable drug products. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.

Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics' sector.

Xellia is the leading supplier of important anti-infectives vancomycin and colistimethate sodium (CMS). Our success and strong market position is built on more than 115 years' of pharmaceutical industry experience.

Xellia Pharmaceuticals' focus its R&D investments within injectable product technologies, as we are committed to researching solutions, which improve patients' quality of life.

Supplying products to more than 70 countries worldwide and with more than 500 customers internationally, Xellia Pharmaceuticals places a high regard on maintaining strong relationships with its customers.

Our sales team serves as the first point of contact for customers, ensuring fast and

accurate delivery of product information; through managing orders to delivery. Xellia Pharmaceuticals' Global Business Operations Team serves as the main point of contact for customers to provide them with specialized support for all technical matters that may be associated with market entry and launch of products.

Working collaboratively with the sales team and cross-functionally with Xellia's internal departments at all sites, Xellia Pharmaceuticals is dedicated to providing reliable outstanding service to its customers at all times.

Active Pharmaceutical Ingredients and Finished Dosage Forms

APIs FDFs

Amphotericin B	Colistimethate sodium dry-filled vials 1 miu, 2 miu, 3 miu
Bacitracin	Colistimethate sodium lyophilized vials 150 mg
Bacitracin zinc	Daptomycin vials 350 mg, 500 mg
Colistimethate sodium	Micafungin* vials 50 mg, 100 mg
	Polymyxin B vials 500.000 units
	Vancomycin Injection ready to use bags 500 mg, 750 mg, 1g, 1.25g, 1.5g, 1.75g, 2g
Polymyxin B sulfate	Vancomycin HCl vials 0.5g, 1g, 5g, 10 g
Tobramycin sulfate	Voriconazole vials 200 mg
Tyrothricin	
Vancomycin hydrochloride	<small>*Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement.</small>

INTERNATIONAL SALES OFFICE: Xellia Pharmaceuticals ApS, Copenhagen, Denmark
Tel: [+45 32 64 55 00](tel:+4532645500) E-mail: sales@xellia.com

LOCAL SALES OFFICES:
www.xellia.com/contact

A company owned by Novo Holdings A/S
www.xellia.com